Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Biehn

Orthopaedic Surgery Queen Creek, AZ Doctor of Osteopathy

NPI 1669637062 CMS profile 29819

37100 N. Gantzel Rd., Ste. 107, Queen Creek, AZ 85140

Open in the dashboard

General payments

$4,737

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Biehn of Queen Creek, AZ is reported in the CMS Open Payments database as having received $4,737 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53 2
2024 General $387 5
2023 General $607 7
2022 General $1,575 5
2021 General $673 19
2020 General $15 1
2019 General $1,427 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Biehn
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jeffrey Biehn were reported at $53. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jeffrey Biehn Orthopaedic Surgery median Middle half National median
2019 $1,427 $644 $140–$2,844 $163
2020 $15 $312 $75–$1,860 $114
2021 $673 $520 $117–$2,495 $132
2022 $1,575 $598 $128–$2,731 $149
2023 $607 $461 $128–$2,264 $160
2024 $387 $497 $134–$2,475 $164
2025 $53 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ImpactOrtho, Inc. $1,395 4 payments
  2. Stryker Corporation $1,178 12 payments
  3. Goode Surgical Inc $1,085 2 payments
  4. Zimmer Biomet Holdings, Inc. $365 11 payments
  5. Encore Medical, LP $148 2 payments
  6. Vericel Corporation $137 3 payments
  7. Smith+Nephew, Inc. $88 2 payments
  8. DePuy Synthes Sales Inc. $85 3 payments
  9. Ferring Pharmaceuticals Inc. $82 4 payments
  10. Dynasplint Systems Inc. $67 2 payments
  11. Other $107 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,362 3 payments
  2. Food and Beverage $2,356 45 payments
  3. Travel and Lodging $19 3 payments
Products named General payments · program years 2019–2025
  1. T2 ALPHA $318 4 payments
  2. MAKO $272 2 payments
  3. HOFFMANN $272 2 payments
  4. Persona Revision $204 8 payments
  5. GAMMA $184 2 payments
  6. T2 $163 1 payment
  7. DJO SURGICAL $148 2 payments
  8. AXSOS $140 1 payment
  9. AUGMENT INJECTABLE $140 1 payment
  10. VARIAX $140 1 payment
  11. Other $966 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

293

Median for Orthopedic Surgery: 203

Drug cost

$1,575

Median for Orthopedic Surgery: $1,433

Branded share of claims

15%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 141 $1,043
Meloxicam Generic 95 $257
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 18 $108
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $107
Cephalexin Generic 13 $61

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$145,635

Of which drugs: $17,551

Medicare patients

353

Average age 74

Services billed

3,720

227 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 27%
Ischemic heart disease 25%
Chronic kidney disease 25%
Depression 24%
Osteoporosis 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 24 28 $15,291
Injection, methylprednisolone acetate, 1 mg J1010 Office 54 2,480 $250
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 11 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record